Jeannie Joughin
Direktor/Vorstandsmitglied bei ImmVirX Pty Ltd.
Profil
Jeannie Joughin is a professional with a doctorate and undergraduate degree from Monash University.
She is currently a Non-Executive Director at ImmVirX Pty Ltd.
and a Principal at OneVentures Management Pty Ltd.
Her former positions include being a Non-Executive Director at Glutagen Pty Ltd.
and Paranta Biosciences Ltd., Vice President at CSL Behring LLC, Marketing Manager at Mayne Pharma Ltd., Clinical Research at Bristol Myers Squibb Co., and Vice President at Enable Injections, Inc. She was also the Chief Operating Officer at Paradigm Biopharmaceuticals Ltd.
from 2020 to 2021.
Aktive Positionen von Jeannie Joughin
Unternehmen | Position | Beginn |
---|---|---|
OneVentures Management Pty Ltd.
OneVentures Management Pty Ltd. Investment ManagersFinance OneVentures Management Pty Ltd. (OneVentures) is a venture capital firm, a susbidiary of Andover Group Pty Ltd was founded in 2006 by Dr Michelle Deaker. The firm is headquartered in Australia. | Private Equity Investor | 01.08.2021 |
ImmVirX Pty Ltd.
ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Jeannie Joughin
Unternehmen | Position | Ende |
---|---|---|
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | Direktor/Vorstandsmitglied | 01.06.2022 |
PARADIGM BIOPHARMACEUTICALS LIMITED | Geschäftsführer | 30.06.2021 |
Glutagen Pty Ltd.
Glutagen Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Glutagen Pty Ltd. develops enzyme therapies for the treatment of gluten intolerance and coeliac disease. The company has two products Glutazyme and Glutaren. The company was founded by Teodor Stelmasiak in 2001 and is headquartered in South Melbourne, Australia. | Direktor/Vorstandsmitglied | 01.02.2020 |
Enable Injections, Inc.
Enable Injections, Inc. Medical SpecialtiesHealth Technology Enable Injections, Inc. develops wearable bolus injectors for investigational use in the pharmaceutical and biotechnology industries to deliver high viscosity, high volume payloads up to 20cc to the subcutaneous tissue. The company was founded by Michael D. Hooven in February 2010 and is headquartered in Cincinnati, OH. | Präsident | 01.01.2019 |
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Präsident | 30.04.2015 |
Ausbildung von Jeannie Joughin
Monash University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
PARADIGM BIOPHARMACEUTICALS LIMITED | Health Technology |
Private Unternehmen | 8 |
---|---|
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Health Technology |
Mayne Pharma Ltd.
Mayne Pharma Ltd. Pharmaceuticals: OtherHealth Technology Mayne Pharma Ltd. manufactures pharmaceutical products. It distributes generic injectables for the oncology market. The company's competitors include Sandoz, Bedford Labs, and Ebewe. It was founded in November 2005 and is headquartered in Melbourne, Australia. | Health Technology |
Bristol Myers Squibb Co. /Australian Pharmaceutical Mfg Ops/ | Health Technology |
Glutagen Pty Ltd.
Glutagen Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Glutagen Pty Ltd. develops enzyme therapies for the treatment of gluten intolerance and coeliac disease. The company has two products Glutazyme and Glutaren. The company was founded by Teodor Stelmasiak in 2001 and is headquartered in South Melbourne, Australia. | Commercial Services |
OneVentures Management Pty Ltd.
OneVentures Management Pty Ltd. Investment ManagersFinance OneVentures Management Pty Ltd. (OneVentures) is a venture capital firm, a susbidiary of Andover Group Pty Ltd was founded in 2006 by Dr Michelle Deaker. The firm is headquartered in Australia. | Finance |
Enable Injections, Inc.
Enable Injections, Inc. Medical SpecialtiesHealth Technology Enable Injections, Inc. develops wearable bolus injectors for investigational use in the pharmaceutical and biotechnology industries to deliver high viscosity, high volume payloads up to 20cc to the subcutaneous tissue. The company was founded by Michael D. Hooven in February 2010 and is headquartered in Cincinnati, OH. | Health Technology |
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | Health Technology |
ImmVirX Pty Ltd.
ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Commercial Services |